Peter H. O'Donnell to Antineoplastic Agents, Immunological
This is a "connection" page, showing publications Peter H. O'Donnell has written about Antineoplastic Agents, Immunological.
Connection Strength
0.827
-
Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108. Cancer. 2020 01 15; 126(2):432-443.
Score: 0.596
-
Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status. Eur Urol Oncol. 2020 06; 3(3):351-359.
Score: 0.155
-
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2020 08 10; 38(23):2658-2666.
Score: 0.039
-
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2019 10 10; 37(29):2592-2600.
Score: 0.037